• Astellas Pharma has cut its financial year operating income forecast to 13.00 billion yen, down from its previous projection of 83.00 billion yen.
• Factoring in the estimation of the operating income was expected to reach 101.41 billion yen, this updated forecast missed estimates significantly.
• Additionally, the firm’s forecast of its net income is 3.00 billion yen, a sharp decline compared to the previous net income of 58.00 billion yen.
• The new net income estimation of 3.00 billion yen also falls short of the original estimate, which was 69.02 billion yen.
• Nevertheless, Astellas Pharma is consistent in its estimation of net sales, with a forecast staying at 1.56 trillion yen.
• This net sales prediction is closely aligned with the estimate, set slightly higher at 1.57 trillion yen.
• In terms of stock, the company has recorded 10 buys, 6 holds and 0 sells.
• It is important to note that comparisons to the company’s past performances are made based on the values reported in the company’s original disclosures.
Astellas Pharma on Smartkarma
Independent analyst Tina Banerjee‘s recent coverage of Astellas Pharma on Smartkarma highlights contrasting sentiments regarding the company’s performance. In a bullish report titled “Astellas Pharma (4503 JP): Some Recent Positive Developments That Will Yield Benefit in Long-Run,” Banerjee acknowledges Astellas’ positive strides, such as the European approval of potential blockbuster drug Veoza and the acquisition of Propella Therapeutics. These developments are seen as crucial steps towards achieving sustainable and accelerated growth in the long term.
However, in a bearish report titled “Astellas Pharma (4503 JP): Underwhelming H1 Result; Massive Cut in FY24 Profit Guidance,” Banerjee expresses concerns over Astellas Pharma‘s H1FY24 performance, citing minimal revenue growth, significant declines in operating and net profits, and a substantial cut in profit forecasts for FY24 due to factors like generic competition and increased expenses. The contrasting analyses shed light on the varied perspectives within the investment community regarding Astellas Pharma‘s future prospects.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astellas Pharma shows strong performance in the areas of dividend and value, with a solid score of 5 and 3, respectively. This indicates that the company is likely to provide stable returns to investors and is reasonably priced. However, Astellas Pharma‘s scores for growth, resilience, and momentum are lower, suggesting challenges in these areas. As such, while the company may offer attractive dividends and be considered a good value, investors may want to consider the potential limitations regarding its growth and ability to withstand market volatility.
Despite facing some hurdles in growth, resilience, and momentum, Astellas Pharma Inc. remains a key player in the pharmaceutical industry. Specializing in various therapeutic fields such as Urology, Immunology, Oncology, and Neuroscience, the company has a global presence with a sizable workforce of over 17,000 employees. Astellas Pharma‘s focus on developing prescription drugs for critical health issues showcases its commitment to advancing medical solutions. With subsidiaries operating in major regions like the US, Europe, and Asia, Astellas Pharma continues to drive innovation and address significant healthcare challenges worldwide.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
